Overview

* Arvinas ( ARVN ) reported Q2 revenue of $22.4 mln, down from $76.5 mln yr ago

* Net loss for Q2 widens to $61.2 mln from $35 mln last year

* Co submitted NDA for vepdegestrant, first PROTAC degrader to reach this stage

Outlook

* Arvinas ( ARVN ) plans to continue market preparations for vepdegestrant

* Company to present vepdegestrant trial data at ESMO Congress October 2025

* Arvinas ( ARVN ) expects to share ARV-102 trial data in 2H 2025

* Company believes cash reserves will fund operations into 2H 2028

Result Drivers

* REVENUE DECLINE - Decreased revenue due to completion of Novartis License Agreement and adjustments in Pfizer collaboration

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $22.40

Revenue mln

Q2 Net -$61.20

Income mln

Q2 $93.90

Operatin mln

g

Expenses

Q2 -$71.50

Operatin mln

g income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 9 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Arvinas Inc ( ARVN ) is $14.00, about 45.6% above its August 5 closing price of $7.61

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)